Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?

References

• van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635–645.
   PubMed Web of Science ®Google Scholar
• Millier A, Schmidt U, Angermeyer MC, et al. Humanistic burden in schizophrenia: a literature review. J Psychiatr Res. 2014 Jul 1;54(1):85–93.
   PubMed Web of Science ®Google Scholar
• Maric NP, Jovicic MJ, Mihaljevic M, et al. Improving current treatments for schizophrenia. Drug Dev Res. 2016;77(7):357–3675.
   PubMed Web of Science ®Google Scholar
• International Classification of Diseases 11th Revision (ICD-11). https://icd.who.int/en. As accessed on 2021 Aug 1
   Google Scholar
• Chen Y-F. Chinese classification of mental disorders (CCMD-3): towards integration in international classification. Psychopathology. 2002;35:171–175.
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull. 2009;35:549–562.
   PubMed Web of Science ®Google Scholar
• Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5:47.
   PubMed Web of Science ®Google Scholar
• Meltzer HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin. 1997;14(1):1–20.
   PubMed Web of Science ®Google Scholar
• Naguy A, Alamiri B. Ultra-treatment resistant schizophrenia- where do we stand? Asian J Psychiatr. 2019;44:95–96.
   PubMed Web of Science ®Google Scholar
• Cerveri G, Gesi C, Mencacci C. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm. Neuropsychiatr Dis Treat. 2019;15:1525–1535.
   PubMed Web of Science ®Google Scholar
• Zisook S, McAdams LA, Kuck J, et al. Depressive symptoms in Schizophrenia. Am J Psychiatry. 1999;156:1736–1743.
   PubMed Web of Science ®Google Scholar
• Hambidge D. Secondary Schizophrenia. PLoS Med. 2005 Sep;2(9):e279.
   PubMed Web of Science ®Google Scholar
• Fuller Torrey E, Yolken RH. Schizophrenia as a pseudogenetic disease: a call for more gene-environmental studies. Psychiatry Res. 2019;278:146–150.
   PubMed Web of Science ®Google Scholar
• Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018 Oct;17(3):341–356.
   PubMed Web of Science ®Google Scholar
• U.S. Food, (FDA) DA. The drug development process | FDA [Internet]. 2019 [cited 2021 May 5]. Available from: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process
   Google Scholar
• Dimasi JA, Feldman L, Seckler A, et al. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010 Mar;87(3):272–277.
   PubMed Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51.
   PubMed Web of Science ®Google Scholar
• Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015 Aug 1;20(8):1027–1034.
   PubMed Web of Science ®Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673–683.
   PubMed Web of Science ®Google Scholar
• Leza JC, Garcia-Bueno B, Bioque M, et al. Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev. 2015 Aug;1(55):612–626.
   Web of Science ®Google Scholar
• Altamura AC, Pozzoli S, Fiorentini A, et al. Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog Neuro Psychopharmacol Biol Psychiatry. 2013 April;5(42):63–70.
   Web of Science ®Google Scholar
• Vidal PM, Pacheco R. The cross-talk between the dopaminergic and the immune system involved in schizophrenia. Front Pharmacol. 2020;11:394.
   PubMed Web of Science ®Google Scholar
• Pollak TA, Drndarski S, Stone JM, et al. Philip McGuire and N Joan Abbott. The blood-brain barrier in psychosis. Lancet Psychiatry. 2018 Jan;5(1):79–92.
   PubMed Web of Science ®Google Scholar
• Shalev H, Serlin Y, Friedman A. Breaching the Blood-Brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol. 2009;2009:278531.
   PubMedGoogle Scholar
• Ganguli R, Yang Z, Shurin G, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 1994 Jan 1;51(1):1–10.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011 Oct 1;70(7):663–671.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–1709.
   PubMed Web of Science ®Google Scholar
• Chase KA, Cone JJ, Rosen C, et al. The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia. BMC Psychiatry. 2016;16:152.
   PubMed Web of Science ®Google Scholar
• Murphy CE, Walker AK, Weickert CS. Neuroinflammation in schizophrenia: the role of nuclear factor kappa B. Transl Psychiatry. 2021;11:528.
   PubMed Web of Science ®Google Scholar
• Upthegrove R, Khandaker GM. Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia. Curr Top Behav Neurosci. 2020;44:49–66.
   PubMedGoogle Scholar
• Fernandes BS, Steiner J, Bernstein HG, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psy. 2016;21(4):554–564.
   PubMed Web of Science ®Google Scholar
• Johnsen E, Fathian F, Kroken RA, et al. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry. 2016;16:60.
   PubMed Web of Science ®Google Scholar
• Fawzi MH, Fawzi MM, Fawzi MM, et al. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011 Nov 30;190(1):91–97.
   PubMed Web of Science ®Google Scholar
• Fan X, Pristach C, Liu EY, et al. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007 Jan 15;149(1–3):267–271.
   PubMed Web of Science ®Google Scholar
• Badoer Emilio. Microglia: Activation in acute and chronic inflammatory states and in response to cardiovascular dysfunction. Int J Biochem Cell Biol. 2010 Oct 1;42(10):1580–1585.
   PubMed Web of Science ®Google Scholar
• Monji A, Kato T, Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63:257–265.
   PubMed Web of Science ®Google Scholar
• Emsley JG, Mitchell BD, Kempermann G, et al. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. Prog Neurobiol. 2005 Apr 1;75(5):321–341.
   PubMed Web of Science ®Google Scholar
• Toro CT, Deakin JFW. Adult neurogenesis and schizophrenia: a window on abnormal early brain development? Schizophr Res. 2007 Feb 1;90(1–3):1–14.
   PubMed Web of Science ®Google Scholar
• Wu MD, Hein AM, Moravan MJ, et al. Adult murine hippocampal neurogenesis is inhibited by sustained IL-1β and not rescued by voluntary running. Brain Behav Immun. 2012 Feb 1;26(2):292–300.
   PubMed Web of Science ®Google Scholar
• Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry. 2014;48:277–286.
   PubMed Web of Science ®Google Scholar
• Van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008 Nov;64(9):820–2. 41.
   PubMed Web of Science ®Google Scholar
• Takano A, Arakawa R, Ito H, et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol. 2010;13:943–950.
   PubMed Web of Science ®Google Scholar
• Doorduin J, de Vries EFJ, Willemsen ATM, et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50(11):1801–1807.
   PubMed Web of Science ®Google Scholar
• Licinio J, Seibyl JP, Altemus M, et al. Elevated CSF levels of interleukin-2
in neuroleptic-free schizophrenic patients. Am J Psychiatry. 1993;150:1408–1419.
   PubMed Web of Science ®Google Scholar
• Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013 Mar 1;47(3):401–406.
   PubMed Web of Science ®Google Scholar
• Schwieler L, Larsson MK, Skogh E, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47:401–406.
   PubMed Web of Science ®Google Scholar
• Garver DL, Tamas RL, Holcomb JA. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology. 2003;28:1515–1520.
   PubMed Web of Science ®Google Scholar
• McAllister CG, Van Kammen DP, Rehn TJ, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995;152:1291–1297.
   PubMed Web of Science ®Google Scholar
• Barak V, Nisman B, Roisman I, et al. Changes in interleukin- 1 β and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol. 1995;6(1):61–69.
   PubMedGoogle Scholar
• Katila H, Appelberg B, Hurme M, et al. Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res. 1994 Apr 1;12(1):29–34.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, McAllister CG, and Pickar D, et al. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res. 1997 May 24;25(2):123–129.
   PubMed Web of Science ®Google Scholar
• Kato T A, Monji A, Mizoguchi Y, et al. Anti-inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a ‘Fire Extinguisher’ in the brain of schizophrenia? Mini-Rev Med Chem. 2011;11:565–574.
   PubMed Web of Science ®Google Scholar
• Ashley LC, Carrier M, Tremblay M-È, et al. The inflamed brain in schizophrenia: the convergence of genetic and environmental risk factors that lead to uncontrolled neuroinflammation. Front Cell Neurosci. 2020;14:274.
   PubMed Web of Science ®Google Scholar
• Pavlović D, Tamburić V, Stojanović I, et al. Oxidative stress as marker of positive symptoms in schizophrenia. Med Biol. 2002;9(2):157–161.
   Google Scholar
• Coughlin JM, Hayes LN, Tanaka T, et al. Reduced superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with early psychosis in association with clinical features. Schizophr Res. 2017 May 1;183:64–69.
   PubMed Web of Science ®Google Scholar
• Akyol A, Herken H, Uz E, et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog Neuro Psychopharmacol Biol Psychiatry. 2002 Jun 1;26(5):995–1005.
   PubMed Web of Science ®Google Scholar
• Ranjekar PK, Hinge A, Hegde MV, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003 Dec 1;121(2):109–122.
   PubMed Web of Science ®Google Scholar
• Khan MM, Evans DR, Gunna V, et al. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr Res. 2002 Nov 1;58(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ben Othmen L, Mechri A, Fendri C, et al. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuro Psychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):155–159.
   PubMed Web of Science ®Google Scholar
• Li H, Chen Q, Ma Y, et al. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci B. 2006;7(12):981–986.
   PubMedGoogle Scholar
• Dadheech G, Mishra S, Gautam S, et al. Oxidative stress, D-Tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J Clin Biochem. 2006;21(2):34–38.
   PubMedGoogle Scholar
• Yao JK, Reddy R, Van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998 Jul 27;80(1):29–39.
   PubMed Web of Science ®Google Scholar
• Buckman TD, Kling AS, Eiduson S, et al. Glutathione peroxidase and CT scan abnormalities in schizophrenia. Biol Psychiatry. 1987;22:1349–1356.
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers. 2006;22(1–2):83–93.
   PubMed Web of Science ®Google Scholar
• Zhu S, Zhao L, Fan Y, et al. Interaction between TNF-alpha and oxidative stress status in first-episode drug-naïve schizophrenia. Psychoneuroendocrinology. 2020;114:10459565.
   Web of Science ®Google Scholar
• Zhu M, Liu Z, Guo Y, et al. Sex difference in the interrelationship between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia. J Neuroinflammation. 2021 Sep 15;18(1):202.
   PubMed Web of Science ®Google Scholar
• Xiu MH, Zezhi L, Da Chun C, et al. Interrelationships between BDNF, Superoxide dismutase, and cognitive impairment in drug-naive first-episode patients with schizophrenia. Schizophr Bull. 2020;46:1498–1510.66.
   PubMed Web of Science ®Google Scholar
• Cruz BF, de Campos-carli SM, de Oliveira AM, et al. Investigating potential associations between neurocognition/social cognition and oxidative stress in schizophrenia. Psychiatry Res. 2021 Apr;298:113832.
   PubMed Web of Science ®Google Scholar
• Laan, W, Grobbee, DE, and Selten , J-P 2010 Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial J Clin Psychiatry 71 5 520–527
   PubMed Web of Science ®Google Scholar
• Webb JE, Stubbe DE, Poncin YB. Aspirin as an adjunctive treatment for childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2013;23:585–586.
   PubMed Web of Science ®Google Scholar
• Müller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010 Aug 1;121(1–3):118–124.
   PubMed Web of Science ®Google Scholar
• Müller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159(6):1029–1034.
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007 Feb 1;90(1–3):179–185.
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Delrahim KK, Bresee CJ, et al. Celecoxib augmentation of continuously Ill patients with schizophrenia. Biol Psychiatry. 2005;57:1594–1596.
   PubMed Web of Science ®Google Scholar
• Bresee CJ, Delrahim K, Maddux RE, et al. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol. 2006;9:343–348.
   PubMed Web of Science ®Google Scholar
• Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004;25(12):609–612.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zheng H, Rengrong W, et al. The effect of minocycline on amelioration of cognitive deficits and proinflammatory cytokines levels in patients with schizophrenia. Schizophr Res. 2019;212:92–98.
   PubMed Web of Science ®Google Scholar
• Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010 Feb;71(2):138–149.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Sullivan KM, McEvoy JP, et al. Adjunctive minocycline in clozapine treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015;35(4):374–381.
   PubMed Web of Science ®Google Scholar
• Miyaoka T, Yasukawa R, Yasuda H, et al. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):304–307.
   PubMed Web of Science ®Google Scholar
• Chaves C, Marque CR, Maia-de-oliveira JP, et al. Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. Schizophr Res. 2015 Feb 1;161(2–3):439–445.
   PubMed Web of Science ®Google Scholar
• Chen X, Xiong Z, Li Z, et al. Minocycline as adjunct therapy for a male patient with deficit schizophrenia. Neuropsychiatr Dis Treat. 2018;14:2697–2701.
   PubMed Web of Science ®Google Scholar
• Miyaoka T, Yasukawa R, Yasuda H, et al. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008;31:287–292.
   PubMed Web of Science ®Google Scholar
• Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, et al. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Res. 2014;215(3):540–546. 30
   PubMed Web of Science ®Google Scholar
• Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomized double-blind placebo-control clinical trials in patients on standard treatment. J Psychopharmacol. 2012;26(9):1185–1193.
   PubMed Web of Science ®Google Scholar
• Deakin B, Suckling J, Tre B, et al. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry. 2018;5:885–894.
   PubMed Web of Science ®Google Scholar
• Drugs@FDA: FDA-Approved Drugs [Internet]. 2009 [cited 2021 May 5]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125276
   Google Scholar
• Miller BJ, Dias JK, Lemos HP, et al. An open-label, pilot trial of adjunctive Tocilizumab in schizophrenia. J Clin Psychiatry. 2016;77:275–276.
   PubMed Web of Science ®Google Scholar
• Girgis RR, Ciarleglio A, Choo T, et al. A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology. 2018;43:1317–1323.
   PubMed Web of Science ®Google Scholar
• Reimer J, Fink T, Bläker M, et al. Successful treatment of psychosis with infliximab in a patient with Crohn’s disease. Schizophr Res. 2009 Apr 1;109(1–3):194–195.
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Mayer C, Gruber HJ, Landl EM, et al. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clinical Pharmacol Ther. 2007 Jun;45(6):319–327.
   PubMed Web of Science ®Google Scholar
• Link A, Ayadhi T, Böhm M, et al. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J. 2006;27:2945–2955.
   PubMed Web of Science ®Google Scholar
• Tajik-Esmaeeli S, Moazen-Zadeh E, Abbasi N; Simvastatin adjunct therapy for negative symptoms of schizophrenia. a randomized double-blind placebo-controlled trial. Int Clin Psychopharmacol. 2017;32:87–94.
   PubMed Web of Science ®Google Scholar
• Chaudhry IB, Husain N, Drake R, et al. Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment:
pilot study. Ther Adv Psychopharmacol. 2014;4(3):110–116.
   PubMedGoogle Scholar
• Vincenzi B, Stock S, Borba CPC, et al. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophr Res. 2014 Nov 1;159(2–3):395–403.
   PubMed Web of Science ®Google Scholar
• Shen H, Rui L, Yan R, et al. Adjunctive therapy with statins in schizophrenia patients: a meta-analysis and implications. Psychiatry Res. 2018 Apr;262:84–93.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Rezaee Z, Dehbozorgi S, et al. Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial. Psychiatry Res. 2014;219(3):431–435.
   PubMed Web of Science ®Google Scholar
• Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. Andrei Alexandrov C V. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4(2):108–122.
   PubMed Web of Science ®Google Scholar
• Yolland COB, Hanratty D, Neill E, et al. Meta-analysis of randomized controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust N Z J Psychiatry. 2020;54(5):453–466.
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Berk M, Venugopal K, et al. Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuro Psychopharmacol Biol Psychiatry. 2015 3;Mar(57):69–75.
   Web of Science ®Google Scholar
• Klauser P, Xin L, Fournier M, et al. N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial. Transl Psychiatry. 2018;8:220.
   PubMed Web of Science ®Google Scholar
• Mullier E, Roine T, Griffa A, et al. N-acetyl-cysteine supplementation improves functional connectivity within the cingulate cortex in early psychosis: a pilot study. Int J Neuropsychopharmacol. 2019;22(8):478–487.
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Dodd S, Bush AI, et al. Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol Med. 2017;47(5):866–876.
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia—a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64:361–368.
   PubMed Web of Science ®Google Scholar
• Farokhnia M, Azarkolah A, Adinehfar F, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013;36(6):185–192.
   PubMed Web of Science ®Google Scholar
• Sepehrmanesh Z, Heidary M, Akasheh N, et al. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: a double-blind, randomized clinical trial. Prog Neuro Psychopharmacol Biol Psychiatry. 2018 Mar;2(82):289–296.
   Web of Science ®Google Scholar
• Breier A, Liffick E, Hummer TA, et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018 Sep 1;199:395–402.
   PubMed Web of Science ®Google Scholar
• Singer P, Shapiro H, Theilla M, et al. Anti-inflammatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intensive Care Med. 2008;34:1580–1592.
   PubMed Web of Science ®Google Scholar
• Berger GE, Proffitt T-M, McConchie M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry. 2007;68(12):1867–1875.
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-Chain −3 fatty acids for indicated prevention of psychotic disorders. A randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–154.
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schäfer MR, Schlögelhofer M, et al. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015;6:7934.
   PubMed Web of Science ®Google Scholar
• Arvindakshan M, Ghate M, Ranjekar PK, et al. Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003 Aug 1;62(3):195–204.
   PubMed Web of Science ®Google Scholar
• Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study
 of Ethyl-Eicosapentaenoic Acid
as supplemental treatment in schizophrenia. Am J Psychiatry. 2002;159:1596–1598.
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, et al. Trial of omega-3 fatty acid (Ethyl Eicosapentaenoic Acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158:2071–2074.
   PubMed Web of Science ®Google Scholar
• Supp AD, Avila Jr S, Mastella GA, et al. Ascorbic acid supplementation attenuates schizophrenia-like symptoms in an animal model induced by ketamine. Int J Dev Neurosci. 2021 Feb;81(1):26–36.
   PubMed Web of Science ®Google Scholar
• Reif A, Schmitt A, Fritzen S, et al. Neurogenesis and schizophrenia: neurogenesis and schizophrenia: dividing neurons in a divided mind? Eur Arch Psychiatry Clin Neurosci. 2007;257:290–299.
   PubMed Web of Science ®Google Scholar
• Locher MR, Alam A. Acute psychosis in an adolescent treated with infliximab for crohn’s disease. Prim Care Companion CNS Disord. 2015;17(4). DOI:https://doi.org/10.4088/PCC.15l01781
   PubMedGoogle Scholar